Browse studies

Find your next paid study

128 recruiting studies matching your filters

Newest first Highest paying

Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots

This study evaluates barriers to early detection of liver cancer.

Hepatocellular Carcinoma

Estimated

~$10 – $750

University of Southern CaliforniaNCT07312162

Phase 1

INTERCEPT-GPC3: Interleukin-15 and -21 Armored Glypican-3 Specific Chimeric Antigen Receptor Expressing Autologous T-cells in Adults With GPC3-positive Solid Tumors

This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors e…

Solid Tumor (Excluding CNS)Hepatocellular CarcinomaLiver Cell Carcinoma+3 more

Estimated

~$10 – $6,250

Seattle Children's HospitalNCT07224568

Phase 1

Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer

This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in live…

Hepatocellular CarcinomaGastrointestinal Cancer MetastaticNeuroendocrine Tumors

Estimated

~$10 – $8,750

Teclison Ltd.NCT02174549

Observational

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion…

Hepatocellular CarcinomaRadiation Exposure

Estimated

~$10 – $6,250

University of TennesseeNCT03686709

Phase 2

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days. Monotherapy C…

Hepatocellular CarcinomaIntrahepatic Cholangiocarcinoma

Estimated

~$10 – $8,750

Virogin Biotech Canada LtdNCT05223816

Phase 1

A Phase 1b/2 Study of Glutamine Antagonist DRP-104 in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Hepatocellular Carcinoma (FLC)

The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clini…

Fibrolamellar Hepatocellular Carcinoma

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06027086

Phase 1

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination wi…

Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more

Estimated

~$10 – $8,750

GI Innovation, Inc.NCT05824975

Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines

This study evaluates a concept called 'Teaching the Teachers' and whether it is helpful in disseminating guidelines on the national and international levels. "…

Hepatocellular Carcinoma

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT05143619